|
Delayed
Nasdaq
23:00:00 30/06/2025 +03
|
5-day change | 1st Jan Change | ||
| 46.99 USD | +0.02% |
|
-.--% | - |
| 12-15 | Immunome jumps after promising results for its desmoid tumor treatment |  |
| 12-01 | Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer | MT |
Company Valuation: SpringWorks Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,655 | 3,476 | 3,020 | 1,616 | 2,630 | 2,687 |
| Change | - | 109.99% | -13.11% | -46.49% | 62.74% | 2.16% |
| Enterprise Value (EV) 1 | 1,328 | 2,917 | 2,589 | 1,024 | 1,975 | 2,233 |
| Change | - | 119.7% | -11.25% | -60.43% | 92.75% | 13.08% |
| P/E | -10.1x | -68.9x | -17.3x | -5x | -7.09x | -10.4x |
| PBR | 5.14x | 6.27x | 7.16x | 2.9x | 4.28x | 5.59x |
| PEG | - | 1x | -0x | -0.1x | 6.65x | 0.3x |
| Capitalization / Revenue | - | 99,312,098x | - | - | 482,854,888x | 14,023,842x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -22.5x | -63.4x | -15x | -3.66x | -5.78x | -8.13x |
| EV / EBIT | -22.4x | -63x | -14.9x | -3.65x | -5.76x | -8.03x |
| EV / FCF | -46.7x | -181x | -40.8x | -11.6x | -17.4x | -20x |
| FCF Yield | -2.14% | -0.55% | -2.45% | -8.62% | -5.73% | -5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -3.81 | -1.053 | -3.586 | -5.206 | -5.15 | -3.482 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 35 | - | - | 5.447 | 191.6 |
| EBITDA 1 | -59.05 | -45.98 | -173 | -279.9 | -341.3 | -274.7 |
| EBIT 1 | -59.24 | -46.32 | -173.5 | -280.7 | -343 | -278.1 |
| Net income 1 | -58.31 | -45.57 | -173.9 | -277.4 | -325.1 | -258.1 |
| Net Debt 1 | -327.7 | -559.1 | -431.4 | -591.8 | -655.5 | -454 |
| Reference price 2 | 38.49 | 72.52 | 61.98 | 26.01 | 36.50 | 36.13 |
| Nbr of stocks (in thousands) | 43,006 | 47,931 | 48,727 | 62,137 | 72,058 | 74,365 |
| Announcement Date | 3/12/20 A | 2/25/21 A | 2/24/22 A | 2/28/23 A | 2/27/24 A | 2/20/25 A |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 3.54B | |
| 19.17x | 4.48x | 10.55x | 0.47% | 82.65B | |
| 20.62x | 4.39x | 13.64x | 2.39% | 60.24B | |
| -17.31x | 25.92x | -17.11x | -.--% | 58.11B | |
| 35.25x | 12x | 23.01x | -.--% | 49.68B | |
| 21.03x | 4.65x | 13.26x | 0.69% | 46.66B | |
| 38.13x | 3.6x | 13.71x | -.--% | 32.63B | |
| 56.56x | 3.61x | 27.99x | -.--% | 25.69B | |
| 68.2x | 7.25x | 44.11x | -.--% | 22.73B | |
| 23.84x | 5.1x | 13.28x | -.--% | 16.51B | |
| Average | 29.50x | 7.89x | 15.83x | 0.39% | 39.85B | |
| Weighted average by Cap. | 23.28x | 8.64x | 12.28x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SWTX Stock
- Valuation SpringWorks Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
